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Introduction
To reduce cancer-related mortality, improving cancer screening is highly prioritized in all developed countries [1] [2] [3] . Population-based screening for gastric, uterine, lung, colon and breast cancer is provided officially in Japan [4] . In addition, many other cancer screening programs are offered privately [5] [6] [7] . [ 18 F]-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging, which is used for patients with cancer, can detect a wide range of tumors [8, 9] . This technology has been also used to screen for cancer in asymptomatic adults, but this effectiveness is not currently well evaluated. As of 2011, approximately 100 facilities in Japan provided FDG-PET as a private and opportunistic screening program [10] .
Because the sole use of FDG-PET imaging to screen cancer has several limitations [11] , the practice guidelines for FDG-PET cancer screening in Japan recommend that it be used alongside other modalities [12] . Therefore, FDG-PET cancer screening typically comprises whole-body FDG-PET in addition to other modalities such as computed tomography (CT), magnetic resonance imaging (MRI), ultrasonography (US), fecal occult blood test (FOBT) and tumor markers. This combined screening process is called ''FDG-PET cancer screening with multimodalities''.
By using these multimodalities, many types of cancer in various organs can be detected in a single examination (detection rate 0.7-2.1 % [13] [14] [15] [16] [17] [18] [19] [20] ), but, admittedly, reports on diagnostic accuracy have been limited. In terms of the diagnostic validity of screening in asymptomatic participants, only Nishizawa et al. [21] reported sensitivity and specificity of FDG-PET cancer screening with multimodalities (81.8 and 82.0 %, respectively). However, their study population was restricted to employee volunteers at one company, with a mean age of 46.7 years, which was considerably younger than what is considered the susceptible age for cancer. To facilitate discussion on the role and limitations of FDG-PET cancer screening with multimodalities, more data from studies of community-dwelling adults who more accurately represent potential participants of this program are necessary.
To determine the diagnostic accuracy of FDG-PET cancer screening with multimodalities for diverse participants, we conducted the present study at a private facility for medical examination in a community and used population-based cancer registry data as the reference.
Study participants and methods

Ethical statement
The study protocol was approved by the ethics committee of Kyoto University Graduate School and Faculty of Medicine (E1339). Information regarding the use of screening data and handling of personal information was posted on the clinic homepage as well as in the waiting room. Participants were informed that data would be used for academic purposes only, and refusal of participation was assured if desired.
Participants
The participants were 1,762 residents of Osaka Prefecture, Japan, who underwent FDG-PET cancer screening with multimodalities for the first time at Higashitemma Clinic, one of the private facilities that provide such screening in Japan, from November 2004 to December 2005, regardless of age and past cancer screening histories. The participants were charged approximately US$2,000 to undergo the screening, which was nearly equal to the amount of medical fee reimbursement for these tests in Japan. Participants understood this and participated autonomously in this screening program. Written informed consent was obtained from all participants.
Cancer screening FDG-PET cancer screening with multimodalities covered whole-body FDG-PET, chest and abdominal CT, brain and pelvic MRI, thyroid, abdominal, and breast US and FOBT. The tumor markers were measured as a way of providing additional information (Table 1) . When levels of these tumor markers exceeded the normal ranges but were not accompanied by abnormal image findings, detailed examinations were not conducted immediately after the screening, but re-examinations were performed after several months. We did not use upper gastrointestinal series and gastroscopy but did measure Helicobacter pylori antigen and serum pepsinogen for detecting atrophic gastritis.
Image acquisition
Whole-body FDG-PET studies were performed on a PET (Allegro, Phillips Medical Systems) or a PET-CT scanner (Discovery ST, GE Healthcare). The participants fasted for more than 4 h and subsequently received an injection of 3.7 MBq/kg FDG. The scan was started 50 min after the FDG injection and performed from the base of the skull to the proximal thigh. Chest and upper abdominal CT scans were performed using an X-ray CT (LightSpeed Ultra 16, GE Healthcare) or PET-CT scanner without contrast media (3.75 mm slices; 512 9 512 matrix size; FOV 50 cm). MRI was performed using a 1.5-T MRI device (Intera 1.5T, [27] . Registry data for participants with cancer included cancer origin, histopathology findings, stage and date of diagnosis.
The participants who had been diagnosed with cancer before screening were excluded from this analysis.
Test performance values
The presence of cancer at screening was defined as cancers that were confirmed within 1 year of screening. The rationale for this was that FDG-PET cancer screening with multimodalities targets various types of cancers and the 1-year definition is used widely in other population-based cancer screenings in Japan, including those for gastric, colorectal and lung cancer [4] .
Statistical methods
The present study primarily used descriptive data analysis (i.e., sensitivity, specificity, positive predictive values for FDG-PET cancer screening with multimodalities and FDG-PET alone). 95 % confidence intervals (CIs) of these proportions were obtained according to the Wilson method using the Web calculator provided by the Oxford Center for Evidence-based Medicine [28] . All data are reported according to the STARD criteria [29] . Table 2 .
Results
Participants
Screening results
Of the 1,762 participants, 12 were excluded due to previous cancer diagnoses. There were identified 277 sites with suspected cancer in 254 of the 1,750 participants. Of these, 232 participants had one site with suspected cancer, 21 had two sites, and 1 had three sites. Of the 254 participants with cancer suspicions, 28 primary cancer sites among the 27 participants were pathologically confirmed as true-positive (including one case with two cancer sites). Of the 1,496 participants who were screened as free from cancer suspicion, five primary cancer regions were noted by the cancer registry, but confirmed as false-negative cases (Fig. 1) . Sensitivity, specificity and positive predictive values were 84.8 % (28 of 33), 86.8 % (1,491 of 1,718) and 10.1 % (28 of 277), respectively, for FDG-PET cancer screening with multimodalities (Table 3) . Specifically, the false-negative rate was 15.2 % (5 of 33) and the falsepositive rate was 13.2 % (227 of 1,718). FDG-PET alone identified the presence of 106 sites with suspected cancer among 106 of the 1,750 participants, 19 of which were identified as true positives. Among 1,644 participants who were screened to be free from suspected cancer, 14 primary cancer regions were identified among 13 participants as false negatives (including one case with two cancer sites) (Fig. 1) . Sensitivity, specificity and positive predictive values were 57.6 % (19 of 33), 94.9 % (1,631 of 1,718) and 17.9 % (19 of 106), respectively, for FDG-PET alone (Table 4) .
Details of 33 sites of cancer identified by the Osaka Cancer Registry are shown in Table 5 . The number of truepositive and false-negative sites was 28 and five, respectively. Of these, one individual showed two sites of cancer (No. 16 and No. 22 in Table 5 ). Of the 28 true-positive sites, one distant metastatic case was identified, while the others were early stage. The prevalence of cancer by age group was high in participants aged 60-70.
Discussion
The present study revealed the diagnostic accuracy of FDG-PET cancer screening with multimodalities in a community setting with linking to the population-based cancer registry data. Sensitivity values for FDG-PET cancer screening with multimodalities and FDG-PET alone were 84.8 and 57.6 %, respectively, while specificity values were 86.8 and 94.9 %, respectively. These findings confirmed that the risk of false negatives by FDG-PET screening alone was reduced by adding multimodalities to FDG-PET, albeit with slightly lower specificity due to the cumulative false-positive cases [30] .
Although integration of various modalities is the main advantage of FDG-PET cancer screening, some consideration is required when evaluating sensitivity and specificity. Sensitivity and specificity results for FDG-PET cancer screening with multimodalities should be carefully interpreted because the calculation method differs from that of the usual single modality screening. While the main advantage of FDG-PET cancer screening with multimodalities is the ability to detect a wide range of cancer types in various organs concurrently, this capability also makes it difficult to evaluate the sensitivity, and especially the specificity, of screening. In general, cancer screening is site-specific, but FDG-PET cancer screening with multimodalities targets all organs. This means that one or more sites with suspected cancer can be detected in one participant. According to the number of cancer cases and sites confirmed by the cancer registry data, we calculated ''the number of cases without cancer'' in the screening. However, ''the number of sites without cancer'' cannot be calculated. Considering these properties of FDG-PET cancer screening with multimodalities, we calculated the sensitivity using the number of cancer sites and the specificity using the number of participants.
In addition, the sensitivity and specificity of FDG-PET cancer screening with multimodalities differ by characteristics of study populations and combination materials with FDG-PET. These issues need critical interpretations when comparing the present findings with that of a similar study. In fact, the findings of Nishizawa et al. [21] were derived from a restricted group of young employees (mean age 46.7 years) at one company. None of their participants were found to have colorectal cancer, the most detectable cancer by FDG-PET cancer screening with multimodalities. Nishizawa et al. explained this discrepancy by stating that most participants had received annual health check-ups including FOBT and that some of them were excluded from their study. In contrast, the present participants were general community-living adults (mean age 55.0 years); consequently, many kinds of cancer including five colorectal cancers were detected, in a manner consistent with other previous studies. Furthermore, the selection of combination materials affects the sensitivity and specificity. Nishizawa et al. examined other combinations with FDG-PET in terms of sensitivity/specificity and concluded that imaging modalities with prostate-specific antigen test were the best. Based on their combination materials (which excluded FOBT), we recalculated our results, which changed the sensitivity and specificity values to 84.8-72.7 % and 86.8-91.9 %, respectively. This shows that it is necessary to consider study populations and combination materials in comparison. This screening potentially detects not only fatal cancers but also non-fatal cancers like thyroid cancer, that even stop growing. In the present results, five of 28 true-positive sites were thyroid cancers. Detection of these indolent cancers may increase unnecessary definitive examinations and reduce participants' quality of life [31] . This means that the effectiveness of cancer screening should not be evaluated only by the number of detectable cases of cancers in the screening. It is desirable to confirm a reduction in mortality rates among the population in which screening is applied, especially for official organized screening programs. The levels of sensitivity and specificity for a cancer screening program represent indirect evidence of its effectiveness [32] ; thus, to establish FDG-PET cancer screening with multimodalities as an option of private opportunistic screening, the sensitivity and specificity of the program must be determined. The potential risk of screening modalities/materials is an important factor to consider when determining the combination. As many imaging modalities involve radiation, radiation exposure is understandably an important concern. This is especially true for Japanese people, because the frequency of diagnostic X-ray usage in Japan is the highest among all developed countries [33] . The radiation dose with FDG-PET is estimated to be 4.2 mSv (0.019 mSv per MBq 9 60 kg 9 3.7 MBq) [34] , equivalent to the dose used for X-ray diagnosis of gastric cancer (3.7-4.6 mSv) [35] . Gotbi et al. [36] estimated that the effective radiation dose for PET-CT was 6.34-9.48 mSv (at 60 kg body weight) in a single whole-body scan, and surmised that many healthy individuals exposed to at least 6.34 mSv would not benefit from the screening if found to be without cancer. Murano et al. [37] estimated radiation exposure as well as the risks and benefits of FDG-PET in cancer screening and concluded that FDG-PET cancer screening was potentially beneficial for examinees, but this benefit varied by age, gender and the type of examination (PET or PET-CT). Although FDG-PET cancer screening with multimodalities is an opportunistic screening based on individual preference, its use should not be expanded to younger populations who possess a relatively low risk of cancer.
Similarly, when selecting the combination tools, the potential risk of screening modalities/materials is an important factor to consider. In this study, two cases of gastric cancer were false-negative. However, these participants were instructed to undertake definitive examinations due to suspicions of chronic atrophic gastritis. In Japan, population-based screening for gastric cancer is conducted using a barium X-ray examination, which inevitably results in radiation exposure. Some facilities that provide FDG-PET cancer screening with multimodalities use gastric fibroscopy to avoid additional radiation exposure [18] , but this is invasive. Our program included neither barium X-ray examination nor gastric fibroscopy to detect gastric cancer. Instead, we used Helicobacter pylori antigen and the serum pepsinogen test to detect chronic atrophic gastritis, the pre-cancerous stage of gastric cancer [38, 39] . The inclusion of a barium X-ray examination or gastric fibroscopy critically affects the sensitivity of this screening program. Further examination is required to select an optimal combination of modalities/materials that also takes into account participant preference and cost.
This study has some limitations. First, this was a singlefacility study. However, study participants were recruited from a variety of regions in Osaka Prefecture and participated autonomously in the screening. This setting was consistent with other private facilities for FDG-PET cancer screening in Japan. Furthermore, the participant age distribution was similar to that observed in the general FDG-PET cancer screening facilities in Japan [18] , so a significant agerelated bias was not likely. A second limitation was that participants who visited hospitals outside of Osaka Prefecture were not followed. However, 60 hospitals designated as regional cancer centers are capable of administering cancer care in Osaka [40] , and all participants were expected to visit one of these hospitals. The Osaka Cancer Registry, the quality of which has been assured by the International Agency for Research on Cancer (IARC), has been utilized widely for research [22, 23, 41, 42] and covers all of these facilities. The third limitation concerns the definition of false-negative cases. In this study, the presence of cancer at screening was defined as the diagnosis of cancer within 1 year of screening and identified in the cancer registry, just as in other studies [22, 23] . Some cancer cases may not have been diagnosed within the year; in fact, our extended followup for another year identified two other cancer cases. Based on this finding, the sensitivity of FDG-PET cancer screening with multimodalities was recalculated, which changed the value from 84.8 to 82.9 %. However, an extended follow-up period may introduce the risk of detecting ''de novo'' cancer developing after the screening.
FDG-PET cancer screening with multimodalities is an innovative method, and thus accuracy, technical properties, safety, efficacy and/or effectiveness and economic attributes need to be assessed when applying this technique to screening asymptomatic populations [43] . At present, the materials and imaging modalities combined with FDG-PET vary slightly by facility, so reports on the accuracy of the screening from more facilities are necessary. Furthermore, from the perspective of screening service quality, a system that constantly reviews the screening accuracy using data from that facility needs to be established. Population-based cancer registries provide assessors of the screening program with reliable external references for that purpose.
Conclusions
FDG-PET cancer screening with multimodalities detected existing asymptomatic cancer with reasonable accuracy. However, the numbers of false-negative and false-positive results were not negligible. While this method serves as one option for opportunistic screening based on individual preference, facilities should inform participants of the relevant information, including the limitations of this program.
